Colon Cancer Flashcards
Risk factors
Polyps IBD Genetic -familial adenomatous polyposis -hereditary non-polyp colon cancer -family history of cancer Diet and lifestyle
Types of polyps
Hyperplastic - inflammatory
Adenomas - precancerous
Dysplasia
Abnormal cells seen with long term IBD
Lifestyle RFs for colon cancer
Obesity EtOH over 30g / day Smoking Diabetes Western diet - high fat, red meat, low fiber
Colorectal cancer epidemiology
3rd most common cancer
Risk increases with age
-greater than 65
Avg lifetime risk of 5%
Recommendation for FAP
Yearly screening for polyps is recommended
Chance of cancer if FAP
100%
More women develop
Right-sided tumors
Two thirds of colon cancers occur in
Left colon
High risk syndromes for colon cancer
HNPCC Polyposis syndromes (FAP or others)
Increased risk items for colon cancer
Personal history
-adenomatous, colon cancer, IBD
Positive family history
Colon cancer screening for person with average risk
Colonoscopy at 50
-repeat in 10 yrs if negative
Colon cancer screening for person with personal history of curative intent resected colorectal cancer
(Cancer was surgically removed)
Colonoscopy in 1 year
(a year after surgery)
Colon cancer screening for person with increased risk
Colonoscopy
-repeat more often than q 10 yrs
Based on number polyps
Presentation of right sided tumors
Bleeding Dull/ill defined abdominal pain Symptomatic anemia -fatigue, weight loss LESS abdominal pain, constipation
Colon cancer screening for person with personal history of curative intent resected colorectal cancer
Colonoscopy in 1 year
Colon cancer screening for person with a personal history of IBD
Initial colonoscopy 8-10 yrs after onset of symptoms
Signs of metastatic disease
RUQ pain Abdominal Distention Early Satiety (feel full) Supraclavicular Adenopathy Periumbilical Nodules
Presentation of left sided tumors
Bleeding Gas pain Decrease in stool caliber Constipation Colonic obstruction
Frequent initial symptoms of colon cancer
Abdominal pain Change in bowel habit Hematochezia or melena Weakness Anemia w/o other GI symptoms Weight loss
Most common sites of metastases
Regional Lymph Nodes
Liver
Lungs
Peritoneum (lining of abdomen)
Signs of metastatic disease
RUQ pain Abdominal Distention Early Satiety Supraclavicular Adenopathy Periumbilical Nodules
Most cases of colon cancer are
Sporadic, not hereditary
Mutations
Oncogenes- KRAS,BRAF
TSGs- P53, APC
Percent of colon cancers that are hereditary
10%
FAP
Rare, 1% of all CRC
Autosomal dominant
Hundreds - thousands of polyps
100% cancer if untreated
***YEARLY screening for polyps
HNPCC
Hereditary NonPolyp Colon Cancer Rare, 1-5% of all CRC Autosomal dominant Less than 100 polyps Lynch Syndrome I -CRC at early stage in particular family Lynch Syndrome II -80-85% chance of CRC over lifetime -Other cancers usually present -Usually diagnosed after cancer -Screening and prophylactic surgery recommended in carriers
Other high risk population groups
IBD
- UC
- Crohns (less than UC)
Dietary preventative measures for colon cancer
High fiber Low fat High antioxidants Calcium rich diet Vitamin D
Preventative measures for CRC
Diet NSAIDs and COX-2 inhibitors -Celecoxib to reduce polyps in FAP Aspirin Postmenopausal hormones Calcium 1000-1200mg if over 50 Vitamin D 400 IU Colectomy
FDA approved drug used to reduce polyps in FAP
Celecoxib
COX-2 inhibitor
Only screening method shown to reduce mortality in CRC
Fecal Occult Blood Test
DRE
Digital Rectal Exam
Annually @ Age 40
Detects ~10% of cancers
Only 7-10cm of anus
Fecal Occult Blood Test
Annual or biannual @ 50 ***Avoid Red Meat 3 types: Guac Dye Heme Porphyrin Immunochemical Assay 70% False Neg for Cancer 90% False Neg for Polyps 1.5% False Pos - Red meat
Flexible Sigmoidoscopy
Examines lower third of colon
MAY reduce mortality
Increases detection rate by 2-3 fold
Average Risk for CRC
Age over 50
No history of adenoma, CRC, or IBD
No family history
Four screening tools for CRC
Digital Rectal Exam
Fecal Occult Blood Test
Flexible Sigmoidoscopy
Total Colonic Exam (colonoscopy)
Poor prognostic factors for CRC
Stage III/IV Disease T4 Disease Positive Margins Lymph node involvement Pre-op CEA (antigen) greater than 5 Rectal bleeding Bowel perforation Bowel obstruction Grade 3,4 lesion
Treatment options for CRC
Surgery -colectomy or lymph node resection Radiation -well est for rectal cancer -adjuvant radiation has no role in colon cancer Chemo -Neoadjuvant -before surgery -Adjuvant -after surgery -In metastatic, used for palliation and to prolong survival
Radiation in CRC
Useful in rectal cancer
***NO ROLE in colon cancer
Tx of Stage I CRC
Routine surveillance
+/- surgery to remove polyps
Tx of Stage II CRC
Consider adjuvant therapy with Capecitabine or 5-FU/LV Clinical Trial or Observation Consider FOLFOX, CapeOx, or FLOX for pts with: T4 or High risk of recurrence
Tx of Stage III CRC
Adjuvant therapy Preferred: FOLFOX or CapeOx Category 1: FLOX Other: 5FU/LV or Capecitabine
Tx of Stage IV CRC
Manage with
chemotherapy
surgery
+/- biologic therapy
FOLFOX
Fluorouracil (bolus and IV)
Leucovorin
Oxaliplatin
FLOX
Fluorouracil (bolus only)
Leucovorin
Oxaliplatin
Leucovorin
Increases activity of 5-FU
(also increases 5-FU’s ADEs - esp GI)
Panitumumab
EGFR Inhibitor
Must check for EGFR and KRAS mutations
Main ADE: acneiform rash
Cetuximab
EGFR Inhibitor
Must check for EGFR and KRAS mutations
Main ADE: acneiform rash
Vascular Endothelial Growth Factor Targeted Therapy
Block angiogenesis and inhibit tumor growth Agents: Bevacizumab Ziv-Aflibercept Regorafenib Class related ADEs: HTN Hematologic (bleeding and thrombosis)
Bevacizumab
Vascular Endothelial Growth Factor Targeted Therapy
Blocks angiogenesis
ADEs:
HTN
Bleeding
Thrombosis
Ziv-Aflibercept
Vascular Endothelial Growth Factor Targeted Therapy
Blocks angiogenesis
ADEs:
HTN
Bleeding
Thrombosis
Regorafenib
Vascular Endothelial Growth Factor Targeted Therapy
Blocks angiogenesis
ADEs:
HTN
Bleeding
Thrombosis
Bolus 5-FU ADEs
Myelosuppression
- neutropenia
- anemia
- decreased platelets
Continuous IV 5-FU ADEs
GI -mucositis -N/V/D Hand-foot syndrome -hands and feet turn red, raw and dry
Capecitabine ADEs
Oral prodrug of 5-FU,
so similar to continuous IV 5-FU ADEs
-GI N/V/D
5-FU and Capecitabine Associated Diarrhea
Caused by abnormal absorption and secretion of fluids and electrolytes.
Prevalence
30-40%
Severe 10-20%
Irinotecan ADEs
Diarrhea caused by acute cholinergic properties - atropine
Delayed - loperamide or lomotil